Adagene Inc.
ADAGHealthcareNASDAQBiotechnology · Last scanned Jun 27, 2026
Scan Results
Daily timeframe1 of 4 indicators bearish as of Jun 26
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. The company carries a $276.8M market cap, placing it firmly in the micro-cap category. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.
Market Cap
$276.8M
Beta
0.59
P/E (TTM)
—
P/E (Fwd)
-8.06
EPS (TTM)
$-0.38
EPS (Fwd)
$-0.52
ROE
-34.4%
ROA
-16.0%
Cash
$75.8M
Total Debt
$6.3M
Free CF
-$10.3M
52W Change
118.2%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $75.8M in cash comfortably exceeding the $6.3M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$10.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -34.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $9.3M to $7.7M.
ADAG's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, ADAG has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing ADAG's risk profile alongside its fundamentals and technical indicators provides a more complete picture.